DFX Intelligence
Private Equity Intelligence
Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.
The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.
Transactions / i•••••• B•••••••••
i•••••• B••••••••• Joins I••••••••• C••••••••• to Evaluate Chemotherapeutic Toxicity in Human Organoids
Exit to a strategic buyerannouncedannounced Mar 24, 2026Fact
What happened
- Target
- i•••••• B•••••••••
- Platform
- not an add-on on record
- Control
- unknown
- Share acquired
- unknown
- Industry
- technology / technology
- Target location
- unknown
- Seller kind
- Sponsor
- Rollover
- unknown
Values, only where disclosed
- Enterprise value
- Not disclosed
- Purchase price
- Not disclosed
- Equity value
- Not disclosed
- Target revenue
- Not disclosed
- Target EBITDA
- Not disclosed
- Multiple
- Not disclosed
Parties and roles
3 named
Buy side
- “i•••••• B••••••••• Joins I••••••••• C••••••••• to Evaluate Chemotherapeutic Toxicity in Human Organoids”
Sell side
- “i•••••• B••••••••• is held by G•••• P•••• Partners (holding evidence https://www.gppfunds.com/private-equity/portfolio-case-studies/)”
Side not stated
- “i•••••• B••••••••• Joins I••••••••• C••••••••• to Evaluate Chemotherapeutic Toxicity in Human Organoids”
Evidence
“i•••••• B••••••••• Joins I••••••••• C••••••••• to Evaluate Chemotherapeutic Toxicity in Human Organoids”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 16, 2026